Related Experiment Video
Updated: Feb 5, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Biology and treatment of BRAF mutant metastatic melanoma
Benjamin Y Kong1,1, Matteo S Carlino1,2,3,1,2,3, Alexander M Menzies2,3,4,2,3,4
1Crown Princess Mary Cancer Care Centre, Westmead, Sydney, NSW 2145, Australia.
Abstract:
BRAF inhibitors were among the first systemic therapies to show clinical benefit in metastatic melanoma. Here, we review the spectrum of BRAF mutations in melanoma, their role in oncogenesis, clinicopathological associations and response to treatment. The differing biology and clinical features of V600E- and V600K-mutated melanoma are outlined. The molecular changes associated with BRAF fusion genes and their response to targeted therapies, as well as the role of immunotherapy in treatment sequencing with targeted therapies are discussed.
Insights
BRAF inhibitors offer clinical benefit for metastatic melanoma. This review covers BRAF mutations, their oncogenic role, and treatment responses, including targeted therapies and immunotherapy sequencing.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- BRAF inhibitors represent a significant advancement in metastatic melanoma treatment.
- Understanding BRAF mutations is crucial for effective therapeutic strategies.
Purpose of the Study:
- To review the spectrum of BRAF mutations in melanoma.
- To discuss their role in oncogenesis, clinicopathological associations, and treatment response.
- To explore BRAF fusion genes and immunotherapy sequencing.
Main Methods:
- Literature review of BRAF mutations in melanoma.
- Analysis of oncogenesis, clinicopathological features, and treatment outcomes.
- Discussion of targeted therapies and immunotherapy.
Main Results:
- BRAF mutations are key drivers in melanoma development.
- Specific mutations (V600E, V600K) exhibit distinct biological and clinical characteristics.
- BRAF fusion genes and immunotherapy sequencing present evolving treatment landscapes.
Conclusions:
- BRAF inhibitors are foundational for metastatic melanoma.
- Personalized treatment approaches considering specific BRAF alterations are essential.
- Integrating targeted therapies with immunotherapy optimizes patient outcomes.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
What is Conservation Biology?
Biological Effects of Radiation
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Applications Of NMR In Biology

